NASDAQ:ONCO
Onconetix, Inc.
Onconetix, Inc.'s revenue fell 67.7% in fiscal 2025 to $815,371 while operating margin rose to −2190.0%, its highest in 3 years. The diluted share count rose 2803.0%.Summary generated from Onconetix, Inc.'s SEC filings. Latest annual report filed Mar 13, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$815,371
Revenue growth−67.7%
Revenue, 5-yr CAGRn/a
Gross margin77.6%
Operating margin−2190.0%
Net margin−1721.0%
ROICn/a
Return on equity−115.5%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+2803.0%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | 0 | 3 | 1 |
| Operating income | −3 | −13 | −36 | −56 | −18 |
| Net income | −3 | −13 | −37 | −59 | −14 |
| Free cash flow | −2 | −9 | −14 | −11 | n/a |
Recent filings
- DEF 14AProxy statement
Oct 7, 2026 - 8-KEntry into a material agreement
Sep 14, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - S-1Registration statement
Aug 12, 2026 - 8-KEntry into a material agreement
Jul 29, 2026 - S-1Registration statement
Jun 9, 2026 - 8-KAmendment to articles or bylaws
May 19, 2026 - 8-KOther events
May 14, 2026